Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b boceprevir plus peginterferon alfa-2b and ribavirin in HIV/HCV coinfected patients
2008-004864-38Phase 2Completed
- Sponsor
- Schering AG
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of boceprevir in hepatitis C virus infection and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Schering AG. Primary endpoint: Sustained virologic response (SVR). Started Jul 2009; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-004864-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004864-38.